ArticleScientific reports2026
Protein content of extracellular vesicles from patients with advanced melanoma changes upon progression to anti-PD1 therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the role of extracellular vesicles (EVs) in predicting melanoma patients' responses to anti-PD1 immunotherapy. Nine patients with advanced melanoma provided blood samples at three stages: before treatment, before the second dose, and either at disease progression or nine months later. EVs were isolated from serum and analyzed using mass-spectrometry proteomics, followed by network and enrichment analyses. Six out of nine patients progressed despite treatment. Before therapy, responders exhibited higher levels of adaptive immune and cell adhesion proteins, while proteins related to UV radiation response were deplected. An eight-protein signature and cellular adhesion markers correlated with longer progression-free survival. After treatment, non-responders had EV proteins enriched in proteasome activity and metabolic pathways, especially glycolysis. Finally, dynamic changes in EV protein over time showed decreased coagulation proteins, along with an increase in MHC proteins in patients with progressive disease. Overall, EV protein profiles differed between responders and non-responders both before and during therapy. These findings suggest that EVs could provide predictive biomarkers and insights into resistance mechanisms, potentially guiding more effective melanoma treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.